Jefferies reiterates Buy on BridgeBio Pharma stock, $110 target

Jefferies reiterated Buy on BridgeBio Pharma with a $110 price target versus a $66.46 share price, citing Phase III analyses supporting BBP-418’s potential in LGMD2I/R9 and more than 90% conviction in full approval by the November 27, 2026 PDUFA date. The firm estimates peak sales above $1 billion and considers that estimate conservative; it also highlighted cardiac benefits and expansion into other indications. Other firms reiterated Buy or raised targets, including Mizuho’s approximately $4 billion U.S. peak-sales estimate for ATTRUBY.

Analysis

The near-term setup is binary, not simply a read-through from encouraging biomarkers: the November 27, 2026 PDUFA is roughly seven weeks away, so any remaining uncertainty around clinical meaningfulness, manufacturing, labeling, or FDA review can dominate the next earnings cycle. Biomarker and cardiac-function signals strengthen the case, but they do not independently establish approval or broad uptake. The key commercial test after approval would be diagnosed-patient reach, payer access, and evidence that functional benefit justifies premium pricing; small rare-disease populations can support high prices but also make launch ramps sensitive to screening and reimbursement.

The bullish case is increasingly visible in analyst ratings and sales estimates, raising the risk that a clean approval is partly priced in while a delay, restrictive label, or safety issue causes a sharp reset. The wide target range is a reminder that valuation depends on uncertain adoption assumptions, not just the regulatory decision. ATTRUBY is a separate value driver: its commercial opportunity may improve if rival programs disappoint, but trial setbacks at Ionis and AstraZeneca should not be treated as proof of durable share capture or as evidence about BBP-418’s FDA odds. Over 6–18 months, realized launch demand and competitive positioning matter more than analyst peak-sales forecasts. Verify the FDA’s review status, label expectations, safety database, and commercial access assumptions before sizing an event trade.

Key Decisions for Investors

• For the next seven weeks, treat BBIO as an event-risk position rather than a straightforward momentum buy. If adding exposure, use a limited position size and consider defined-risk protection; option premiums and implied volatility are not supplied, so do not assume a call spread is attractively priced.
• Do not chase analyst target revisions as a standalone catalyst. Track FDA communications and the November 27 PDUFA; a delay, narrower-than-expected label, or safety concern would falsify the near-term bullish thesis and likely outweigh supportive biomarker analyses.
• After an approval, look for evidence of patient identification, reimbursement, and early prescription uptake before underwriting the stated peak-sales opportunity. Weak launch conversion or access friction would challenge the pricing-power thesis even with a favorable label.
• Avoid a BBIO-versus-IONS/AZN pair based solely on the cited trial setbacks: those events do not establish comparable exposure or a direct competitive relationship to BBP-418. Reassess ATTRUBY separately against competing ATTR-CM treatments as commercial data emerge.